Theriva Biologics Announces $4.0M Warrant Inducement Transaction.

Theriva Biologics has announced a warrant inducement transaction for $4.0 million in gross proceeds. Existing institutional investors will exercise warrants to purchase 7,360,460 shares of common stock at a reduced exercise price of $0.54 per share. The offer remains open until October 16, 2025, for up to an additional $0.4 million in gross proceeds.

Theriva Biologics (NYSE American: TOVX) has announced a warrant inducement transaction, generating approximately $4.0 million in gross proceeds. The company has entered into an agreement with existing institutional investors to exercise up to 7,360,460 warrants at a reduced price of $0.54 per share, according to the company's press release.

The offer to exercise these warrants remains open until October 16, 2025, with an option to raise up to an additional $0.4 million in gross proceeds. In exchange, investors will receive new unregistered warrants to purchase up to 14,720,920 shares at the same $0.54 exercise price. These new warrants will be exercisable after stockholder approval and will expire five years after the approval date.

The transaction aims to provide Theriva with immediate working capital and general corporate purposes. The closing of the transaction is expected on or about October 17, 2025, subject to customary closing conditions. Key dependencies include shareholder approval and successful SEC registration, which will determine when the new warrants can be exercised and converted into stock.

The deal converts existing warrants into immediate cash at a reduced exercise price and grants replacement warrants that total twice the number of shares underlying the exercised warrants. The company intends to use the net proceeds for working capital and general corporate purposes. The new warrants and underlying shares remain unregistered until the company files a registration statement.

Investors should monitor the registration filing and stockholder approval outcomes over the next several weeks, as these will affect when holders can convert the new warrants and whether the company obtains additional cash from future exercises.